Circulating tumour cells for the prediction of the response to radiation therapy in prostate cancer.

Circulating tumour cells (CTCs) have emerged as a promising biomarker for assessing prognosis and predicting therapeutic efficacy in various cancers, including metastatic prostate cancer. However, predicting patient response to treatment, including radiation therapy (RT), remains a significant clinical challenge. This review explores the value of CTCs as prognostic markers in RT for prostate cancer, discussing their detection methods, biological significance, clinical relevance, and future implications.